NEW HAVEN, Conn., Feb. 8, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael Kishbauch, President and Chief Executive Officer of Achillion, will provide a corporate update at the following upcoming investor conferences:
- 14th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2012 at 10:30 a.m. ET at the Waldorf=Astoria Hotel in New York City, NY;
- Leerink Swan 2012 Global Healthcare Conference on Wednesday, February 15, 2012 at 9:00 a.m. ET at the Waldorf=Astoria Hotel in New York City, NY; and
- Citi 2012 Global Health Care Conference on Monday, February 27, 2012 at 3:30 p.m. ET at the Waldorf=Astoria Hotel in New York City, NY.
The live audio broadcasts and the subsequent archived webcasts of the Company's presentations will be available on the Company's website, http://www.achillion.com, under the "News Center" section. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.
About Achillion Pharmaceuticals
Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit www.achillion.com or call 1-203-624-7000.